Skip to Main Content

Paper Details

Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo.
Mol Cancer Ther
18
2019
ABT-263, BCL, BCL-2/XL, ERBB2, HER2, HER2 protein, HER2+, HER2+ breast cancer, HER2-expressing patient-derived breast cancer xenograft models, PDXs, T, T-DM1, advanced and/or metastatic breast cancer, anti-apoptotic BCL-2 family proteins, breast cancer, breast tumor, metastatic, metastatic breast tumors, metastatic tumor, navitoclax, patient, patients, tumor, tumors
Author NameAffiliation
Dennis J SlamonDavid Geffen School of Medicine at university of california los angeles
Joan S BruggeHarvard Medical School
  • 1 - 2

Datasets

Release 1.2